Clinical Trials

This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat Severe Aplastic Anemia.

Are you scheduled for a stem cell transplant with cord blood? This study will assess the safety and effectiveness of certain cord blood transplants. The study will help researchers learn the best methods for collecting, storing, and using cord blood in transplants. To participate in this study, you must have a disorder that compromises your body’s ability to make blood cells. This study is located in Bethesda, Maryland.

Would you like to donate blood for a study of stored red blood cells? This study is evaluating how blood donors affect the stability of stored red blood cells. After collecting a blood sample from a healthy donor, researchers treat the red blood cells with a B vitamin called biotin and then store the sample. After about 1 week, some of the cells are transfused back into the donor to check how many of the red blood cells are still healthy after storage. After a few more weeks, more of the stored cells are transfused and tested again. To participate, your blood must meet certain requirements and you must be healthy, 18 years old or older, and weigh at least 110 pounds. This study is located in Pittsburgh, Pennsylvania.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.